Answers are grounded in this paper and cite their sources.
Analysis reveals lymphoma-derived extracellular vesicles inhibit CAR T cell function, suggesting potential resistance mechanisms.
CD19-targeting CAR T cell therapy has shown remarkable efficacy in the treatment of relapsed/refractory B cell lymphoma. However, a proportion of patients exhibit resistance to treatment. We investigate the impact of lymphoma-derived Extracellular Vesicles (EV) on CD19-targeting CAR T cell function in vitro . We demonstrate that lymphoma-EV express B cell markers such as CD19 and CD20, which can be transferred to the CAR T cell membrane. In co-culture experiments, lymphoma-EV suppress the tumour-killing capacity of CAR T cells.
No takes yet. Share an insight, caveat, or question.
Siddika et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: